Fernando Civeira Selected Research

Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial)

1/2018	Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight.
8/2014	Serum lipid responses to weight loss differ between overweight adults with familial hypercholesterolemia and those with familial combined hyperlipidemia.
4/2014	Bile acid synthesis precursors in familial combined hyperlipidemia: the oxysterols 24S-hydroxycholesterol and 27-hydroxycholesterol.
6/2012	Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia.
9/2011	Type II interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions.
9/2010	Iron deposits and dietary patterns in familial combined hyperlipidemia and familial hypertriglyceridemia.
5/2010	FABP4 plasma levels are increased in familial combined hyperlipidemia.
2/2010	Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia.
11/2008	Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.
1/2007	Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fernando Civeira Research Topics

Disease

43	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 11/2022 - 04/2002
29	Hypercholesterolemia 11/2022 - 08/2003
23	Cardiovascular Diseases (Cardiovascular Disease) 09/2021 - 04/2002
19	Atherosclerosis 01/2022 - 09/2003
15	Obesity 01/2022 - 02/2009
14	Dyslipidemias (Dyslipidemia) 11/2022 - 07/2002
11	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 02/2009
11	Hypertriglyceridemia 12/2020 - 02/2009
11	Xanthomatosis (Xanthoma) 01/2018 - 03/2004
10	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 01/2018 - 01/2007
9	Insulin Resistance 08/2022 - 11/2009
8	Arteriosclerosis 11/2022 - 01/2017
8	Type 2 Diabetes Mellitus (MODY) 04/2021 - 01/2007
8	Hypertension (High Blood Pressure) 01/2021 - 04/2002
7	Inborn Genetic Diseases (Disease, Hereditary) 12/2020 - 03/2004
7	Coronary Disease (Coronary Heart Disease) 01/2018 - 03/2004
7	Hyperlipidemias (Hyperlipidemia) 01/2016 - 06/2002
6	Overweight 04/2021 - 02/2009
5	Body Weight (Weight, Body) 09/2021 - 08/2014
5	Atherosclerotic Plaque (Atheroma) 01/2020 - 01/2007
4	Inflammation (Inflammations) 01/2022 - 06/2002
4	Injection Site Reaction 01/2019 - 11/2015
4	Pancreatitis 01/2019 - 01/2013
4	Homozygous Familial Hypercholesterolemia 01/2019 - 03/2015
3	Hyperlipoproteinemia Type III (Broad Beta Disease) 05/2021 - 06/2012
3	Prediabetic State (Prediabetes) 04/2021 - 01/2020
3	Coronary Artery Disease (Coronary Atherosclerosis) 11/2020 - 11/2002
3	Weight Loss (Weight Reduction) 01/2020 - 08/2014
3	Myocardial Infarction 03/2019 - 01/2007
3	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 01/2019 - 01/2018
3	Iron Overload 09/2018 - 02/2010
3	Rare Diseases (Rare Disease) 01/2018 - 01/2016
3	Diabetes Mellitus 01/2015 - 11/2008
3	Carotid Artery Diseases 07/2010 - 11/2009
2	Hyperlipoproteinemias 08/2021 - 06/2012
2	Stroke (Strokes) 01/2017 - 09/2003
2	Cholestasis 09/2014 - 09/2014
2	Hyperlipoproteinemia Type IV (Type IV, Hyperlipoproteinemia) 09/2010 - 02/2010

Drug/Important Bio-Agent (IBA)

36	LipidsIBA 11/2022 - 04/2002
31	LDL CholesterolIBA 11/2022 - 11/2002
19	oxidized low density lipoproteinIBA 01/2022 - 04/2002
17	CholesterolIBA 01/2022 - 10/2006
17	Triglycerides (Triacylglycerol)IBA 09/2021 - 11/2008
12	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2021 - 06/2014
12	Apolipoproteins E (ApoE)IBA 08/2021 - 11/2007
12	Apolipoproteins B (ApoB)IBA 08/2021 - 10/2005
11	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2003
11	LDL Receptors (LDL Receptor)IBA 12/2016 - 08/2003
9	Lipoproteins (Lipoprotein)IBA 09/2020 - 03/2004
7	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 02/2009
7	ApolipoproteinsIBA 12/2016 - 11/2002
6	SterolsIBA 01/2018 - 08/2014
5	HDL CholesterolIBA 11/2022 - 07/2002
5	HDL LipoproteinsIBA 11/2020 - 02/2009
4	Lipoprotein(a)IBA 01/2022 - 07/2014
4	Insulin (Novolin)FDA Link 01/2022 - 01/2015
4	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 09/2013
4	evolocumabIBA 09/2020 - 01/2014
4	Atorvastatin (Lipitor)FDA Link 12/2019 - 06/2002
4	Biomarkers (Surrogate Marker)IBA 06/2019 - 07/2010
4	IronIBA 09/2018 - 11/2009
4	Ferritins (Ferritin)IBA 09/2018 - 02/2010
4	Phytosterols (Plant Sterols)IBA 01/2016 - 05/2014
3	CarbohydratesIBA 04/2021 - 01/2020
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 12/2020 - 01/2015
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 06/2019 - 07/2010
3	PCSK9 InhibitorsIBA 05/2019 - 08/2017
3	NucleotidesIBA 01/2019 - 11/2017
3	Apolipoprotein B-100 (Apo B 100)IBA 01/2019 - 11/2002
3	ProteomeIBA 06/2014 - 11/2009
2	OxysterolsIBA 01/2022 - 04/2014
2	27-hydroxycholesterolIBA 01/2022 - 04/2014
2	24-hydroxycholesterolIBA 01/2022 - 04/2014
2	maltodextrinIBA 04/2021 - 01/2020
2	isomaltulose (palatinose)IBA 04/2021 - 01/2020
2	MaltoseIBA 04/2021 - 01/2020
2	DextrinsIBA 04/2021 - 01/2020
2	Bile Acids and Salts (Bile Acids)IBA 01/2021 - 04/2014
2	Antihypertensive Agents (Antihypertensives)IBA 10/2020 - 03/2020
2	CalciumIBA 01/2020 - 03/2016
2	Phosphatidylcholine-Sterol O-Acyltransferase (Lecithin Cholesterol Acyltransferase)IBA 11/2019 - 07/2002
2	Proprotein Convertase 9IBA 01/2019 - 12/2016
2	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2019 - 07/2018
2	MicroRNAs (MicroRNA)IBA 01/2017 - 07/2016
2	alirocumabIBA 01/2016 - 11/2015
2	Ezetimibe (Zetia)FDA Link 01/2016 - 01/2012
2	Biological ProductsIBA 06/2014 - 07/2012
2	Phospholipids (Phosphatides)FDA LinkGeneric 09/2013 - 07/2010
2	AntioxidantsIBA 09/2012 - 07/2012
2	Messenger RNA (mRNA)IBA 09/2011 - 11/2007
2	CytokinesIBA 09/2011 - 06/2009
2	EnzymesIBA 02/2010 - 09/2003
2	C-Reactive ProteinIBA 01/2007 - 06/2002
2	chitotriosidaseIBA 01/2007 - 09/2003
2	BezafibrateIBA 12/2005 - 06/2002
1	TitaniumIBA 01/2022

Therapy/Procedure

14	Therapeutics 01/2022 - 06/2014
2	Secondary Prevention 11/2022 - 08/2020
2	Glycemic Control 08/2022 - 01/2020
2	Mediterranean Diet 05/2018 - 11/2017